BACKGROUND: Enthusiasm for the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as an adjunctive treatment in type 1 diabetes (T1D) has been offset by the possible increased risk of diabetic ketoacidosis (DKA). Since pump-treated T1D patients are susceptible to DKA due to infusion site problems, this study was undertaken to assess how treatment with SGLT2i affects patterns of early metabolic decompensation following suspension of basal insulin. METHODS: Ten T1D participants (age 19-35 years, duration 10 ± 8 years, A1c 7.4% ± 0.8%) underwent overnight pump suspension studies before and after treatment with canagliflozin (CANA). On both nights, basal insulin was suspended at 3 AM and plasma glucose (PG), β-hydroxybutyrate (BHB), free fatty acids (FFA), plasma insulin (PI), and glucagon were measured. Studies were terminated 6 h after suspension or if PG rose to >350 mg/dL or BHB >2.5 mmol/L. RESULTS: PI levels at the start of suspension were reduced by 30% after CANA treatment (44 ± 11 uU/mL vs. 31 ± 10 uU/mL, P < 0.01), but baseline PG, BHB, FFA, and glucagon levels were not significantly different. During the suspension, PG rose from 104 ± 10 to 301 ± 21 mg/dL before treatment, but only from 109 ± 8 to 195 ± 14 mg/dL after treatment (P = 0.002 vs. pretreatment values). On the other hand, CANA treatment did not significantly affect the magnitude of increases in FFA, BHB, and glucagon levels during the suspension study. CONCLUSION: These data indicate that SGLT2i do not accelerate the rate of ketogenesis following the interruption of basal insulin infusion in T1D. Rather, the failure of patients to promptly recognize early metabolic decompensation relates to the much more gradual rise in PG levels.
BACKGROUND: Enthusiasm for the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as an adjunctive treatment in type 1 diabetes (T1D) has been offset by the possible increased risk of diabetic ketoacidosis (DKA). Since pump-treated T1D patients are susceptible to DKA due to infusion site problems, this study was undertaken to assess how treatment with SGLT2i affects patterns of early metabolic decompensation following suspension of basal insulin. METHODS: Ten T1D participants (age 19-35 years, duration 10 ± 8 years, A1c 7.4% ± 0.8%) underwent overnight pump suspension studies before and after treatment with canagliflozin (CANA). On both nights, basal insulin was suspended at 3 AM and plasma glucose (PG), β-hydroxybutyrate (BHB), free fatty acids (FFA), plasma insulin (PI), and glucagon were measured. Studies were terminated 6 h after suspension or if PG rose to >350 mg/dL or BHB >2.5 mmol/L. RESULTS: PI levels at the start of suspension were reduced by 30% after CANA treatment (44 ± 11 uU/mL vs. 31 ± 10 uU/mL, P < 0.01), but baseline PG, BHB, FFA, and glucagon levels were not significantly different. During the suspension, PG rose from 104 ± 10 to 301 ± 21 mg/dL before treatment, but only from 109 ± 8 to 195 ± 14 mg/dL after treatment (P = 0.002 vs. pretreatment values). On the other hand, CANA treatment did not significantly affect the magnitude of increases in FFA, BHB, and glucagon levels during the suspension study. CONCLUSION: These data indicate that SGLT2i do not accelerate the rate of ketogenesis following the interruption of basal insulin infusion in T1D. Rather, the failure of patients to promptly recognize early metabolic decompensation relates to the much more gradual rise in PG levels.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: Helena W Rodbard; Anne L Peters; April Slee; Anjun Cao; Shana B Traina; Maria Alba Journal: Diabetes Care Date: 2016-11-29 Impact factor: 19.112
Authors: Bruce A Perkins; David Z I Cherney; Helen Partridge; Nima Soleymanlou; Holly Tschirhart; Bernard Zinman; Nora M Fagan; Stefan Kaspers; Hans-Juergen Woerle; Uli C Broedl; Odd-Erik Johansen Journal: Diabetes Care Date: 2014-03-04 Impact factor: 19.112
Authors: Michael J Jurczak; Hui-Young Lee; Andreas L Birkenfeld; Francois R Jornayvaz; David W Frederick; Rebecca L Pongratz; Xiaoxian Zhao; Gilbert W Moeckel; Varman T Samuel; Jean M Whaley; Gerald I Shulman; Richard G Kibbey Journal: Diabetes Date: 2011-03 Impact factor: 9.461
Authors: T R Pieber; S Famulla; J Eilbracht; J Cescutti; N Soleymanlou; O E Johansen; H J Woerle; U C Broedl; S Kaspers Journal: Diabetes Obes Metab Date: 2015-06-24 Impact factor: 6.577
Authors: Laura M Nally; Jennifer L Sherr; Michelle A Van Name; Anisha D Patel; William V Tamborlane Journal: Expert Rev Clin Pharmacol Date: 2019-05 Impact factor: 5.045
Authors: Stephan Siebel; Alfonso Galderisi; Neha S Patel; Lori R Carria; William V Tamborlane; Jennifer L Sherr Journal: Diabetes Technol Ther Date: 2019-01-28 Impact factor: 6.118
Authors: Ghasem Yadegarfar; Mark Livingston; Gabriela Cortes; Ramadan Alshames; Kate Leivesley; Ann Metters; Linda Horne; Tom Steele; Adrian H Heald Journal: Cardiovasc Endocrinol Metab Date: 2021-03-25
Authors: Anne L Peters; Darren K McGuire; Thomas Danne; Jake A Kushner; Helena W Rodbard; Ketan Dhatariya; Sangeeta Sawhney; Phillip Banks; Wenjun Jiang; Michael J Davies; Pablo Lapuerta Journal: Diabetes Care Date: 2020-09-14 Impact factor: 19.112
Authors: Moshe Phillip; Chantal Mathieu; Marcus Lind; Eiichi Araki; Paolo di Bartolo; Richard Bergenstal; Simon Heller; Lars Hansen; Markus Florian Scheerer; Fredrik Thoren; Niki Arya; John Xu; Nayyar Iqbal; Paresh Dandona Journal: Diabetes Obes Metab Date: 2020-11-24 Impact factor: 6.577